Tumor suppressor WWOX and p53 alterations and drug resistance in glioblastomas

Frontiers in Oncology

Volumn 3 MAR, Issue , 2013, Pages

  Chiang, Ming Fu ^a,b   Chou, Pei Yi ^c   Wang, Wan Jen ^c   Sze, Chun I ^c   Chang, Nan Shan ^c,d,e  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

^e NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Glioblastoma multiforme; P53; Temozolomide resistance; Tumor suppressor; WWOX

Indexed keywords

3 METHYLADENINE; 6 O METHYLGUANINE; 7 METHYLGUANINE; ALPHA SMOOTH MUSCLE ACTIN; BETA INTERFERON; CD133 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DISHEVELLED 2; ETIRACETAM; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN P53; PROTEIN P73; REACTIVE OXYGEN METABOLITE; RESVERATROL; SMAD4 PROTEIN; STAT3 PROTEIN; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR WWOX; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER GROWTH; CELL CYCLE ARREST; CELL DEATH; CELL MIGRATION; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG SENSITIVITY; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; NONHUMAN; OXIDATIVE STRESS;

EID: 84884228501     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00043     Document Type: Article

References (87)

1. Agnihotri, S., Gajadhar, A. S., Ternamian, C., Gorlia, T., Diefes, K. L., Mischel, P. S., et al. (2012). Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J. Clin. Invest. 122, 253-266.
2. Aoubala, M., Murray-Zmijewski, F., Khoury, M. P., Fernandes, K., Perrier, S., Bernard, H., et al. (2011). p53 directly transactivates Delta133p53alpha, regulating cell fate outcome in response to DNA damage. Cell Death Differ. 18, 248-258.
3. Aqeilan, R. I., Donati, V., Gaudio, E., Nicoloso, M. S., Sundvall, M., Korhonen, A., et al. (2007). Association of Wwox with ErbB4 in breast cancer. Cancer Res. 67, 9330-9336.
4. Aqeilan, R. I., Kuroki, T., Pekarsky, Y., Albagha, O., Trapasso, F., Baffa, R., et al. (2004). Loss of WWOX expression in gastric carcinoma. Clin. Cancer Res. 10, 3053-3058.
5. Beier, D., Schulz, J. B., and Beier, C. P. (2011). Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol. Cancer 10, 128.
6. Blough, M. D., Beauchamp, D. C., Westgate, M. R., Kelly, J. J., and Cairncross, J. G. (2011). Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. J. Neurooncol. 102, 1-7.
7. Bourdon, J. C. (2007). p53 and its isoforms in cancer. Br. J. Cancer 97, 277-282.
8. Bourdon, J. C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., et al. (2005). p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19, 2122-2137.
9. Bouteille, N., Driouch, K., Hage, P. E., Sin, S., Formstecher, E., Camonis, J., et al. (2009). Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein. Oncogene 28, 2569-2580.
10. Caporali, S., Falcinelli, S., Starace, G., Russo, M. T., Bonmassar, E., Jiricny, J., et al. (2004). DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol. Pharmacol. 66, 478-491.
11. Chang, J. Y., Chiang, M. F., Lin, S. R., Lee, M. H., He, H., Chou, P. Y., et al. (2012). TIAF1 self-aggregation in peritumor capsule formation, spontaneous activation of SMAD-responsive promoter in p53-deficient environment, and cell death. Cell Death Dis. 3, e302.
12. Chang, J. Y., He, R. Y., Lin, H. P., Hsu, L. J., Lai, F. J., Hong, Q., et al. (2010). Signaling from membrane receptors to tumor suppressor WW domain-containing oxidoreductase. Exp. Biol. Med. (Maywood) 235, 796-804.
13. Chang, N. S., Doherty, J., Ensign, A., Lewis, J., Heath, J., Schultz, L., et al. (2003). Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses. Biochem. Pharmacol. 66, 1347-1354.
14. Chang, N. S., Hsu, L. J., Lin, Y. S., Lai, F. J., and Sheu, H. M. (2007). WW domain-containing oxidoreductase: a candidate tumor suppressor. Trends Mol. Med. 13, 12-22.
15. Chang, N. S., Pratt, N., Heath, J., Schultz, L., Sleve, D., Carey, G. B., et al. (2001). Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J. Biol. Chem. 276, 3361-3370.
16. Chang, N. S., Schultz, L., Hsu, L. J., Lewis, J., Su, M., and Sze, C. I. (2005a). 17beta-Estradiol upregulates and activates WOX1/WWOXv1 and WOX2/WWOXv2 in vitro: potential role in cancerous progression of breast and prostate to a premetastatic state in vivo. Oncogene 24, 714-723.
17. Chang, N. S., Doherty, J., Ensign, A., Schultz, L., Hsu, L. J., and Hong, Q. (2005b). WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J. Biol. Chem. 280, 43100-43108.
18. Chen, J., Li, Y., Yu, T. S., McKay, R. M., Burns, D. K., Kernie, S. G., et al. (2012). A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526.
19. Chiang, M. F., Yeh, S. T., Liao, H. F., Chang, N. S., and Chen, Y. J. (2012). Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. Biomed. Pharmacother. 66, 433-438.
20. Comer, K. A., Dennis, P. A., Armstrong, L., Catino, J. J., Kastan, M. B., and Kumar, C. C. (1998). Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein. Oncogene 16, 1299-1308.
21. Del Mare, S., Kurek, K. C., Stein, G. S., Lian, J. B., and Aqeilan, R. I. (2011). Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma. Am. J. Cancer Res. 1, 585-594.
22. Delpech, B., Laquerriere, A., Maingonnat, C., Bertrand, P., and Freger, P. (2002). Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. Anticancer Res. 22, 2423-2427.
23. Donati, V., Fontanini, G., Dell'Omodarme, M., Prati, M. C., Nuti, S., Lucchi, M., et al. (2007). WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin. Cancer Res. 13, 884-891.
24. Donovan, L. K., and Pilkington, G. J. (2012). CD133: holy of grail of neuro-oncology or promiscuous red-herring? Cell Prolif. 45, 527-537.
25. Fabbri, M., Iliopoulos, D., Trapasso, F., Aqeilan, R. I., Cimmino, A., Zanesi, N., et al. (2005). WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 15611-15616.
26. Friedman, H. S., Kerby, T., and Calvert, H. (2000). Temozolomide and treatment of malignant glioma. Clin. Cancer Res. 6, 2585-2597.
27. Fujikane, R., Sanada, M., Sekiguchi, M., and Hidaka, M. (2012). The identification of a novel gene, MAPO2, that is involved in the induction of apoptosis triggered by O6-methylguanine. PLoS ONE 7:e44817. doi:10.1371/journal.pone.0044817
28. Fukushima, T., Takeshima, H., and Kataoka, H. (2009). Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res. 29, 4845-4854.
29. Ghosh, A., Stewart, D., and Matlashewski, G. (2004). Regulation of human p53 activity and cell localization by alternative splicing. Mol. Cell. Biol. 24, 7987-7997.
30. Gjerset, R. A., Turla, S. T., Sobol, R. E., Scalise, J. J., Mercola, D., Collins, H., et al. (1995). Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol. Carcinog. 14, 275-285.
31. Goellner, E. M., Grimme, B., Brown, A. R., Lin, Y. C., Wang, X. H., Sugrue, K. F., et al. (2011). Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair. Cancer Res. 71, 2308-2317.
32. Gourley, C., Paige, A. J., Taylor, K. J., Ward, C., Kuske, B., Zhang, J., et al. (2009). WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res. 69, 4835-4842.
33. Guler, G., Uner, A., Guler, N., Han, S. Y., Iliopoulos, D., Hauck, W. W., et al. (2004). The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 100, 1605-1614.
34. Haar, C. P., Hebbar, P., Wallace, G. C. IV, Das, A., Vandergrift, W. A. III, Smith, J. A., et al. (2012). Drug resistance in glioblastoma: a mini review. Neurochem. Res. 37, 1192-1200.
35. Hagemann, C., Anacker, J., Ernestus, R. I., and Vince, G. H. (2012). A complete compilation of matrix metalloproteinase expression in human malignant gliomas. World J. Clin. Oncol. 3, 67-79.
36. Happold, C., Roth, P., Wick, W., Schmidt, N., Florea, A. M., Silginer, M., et al. (2012). Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J. Neurochem. 122, 444-455.
37. Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., et al. (2008). Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26, 4189-4199.
38. Hirose, Y., Berger, M. S., and Pieper, R. O. (2001). p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 61, 1957-1963.
39. Holt, S. V., Logié, A., Odedra, R., Heier, A., Heaton, S. P., Alferez, D., et al. (2012). The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br. J. Cancer 106, 858-866.
40. Hong, Q., Hsu, L. J., Schultz, L., Pratt, N., Mattison, J., and Chang, N. S. (2007). Zfra affects TNF-mediated cell death by interacting with death domain protein TRADD and negatively regulates the activation of NF-kappaB, JNK1, p53 and WOX1 during stress response. BMC Mol. Biol. 8:50. doi:10.1186/1471-2199-8-50
41. Hong, Q., Sze, C. I., Lin, S. R., Lee, M. H., He, R. Y., Schultz, L., et al. (2009). Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS ONE 4:e5755. doi:10.1371/journal.pone.0005755
42. Hsu, L. J., Schultz, L., Hong, Q., Van Moer, K., Heath, J., Li, M. Y., et al. (2009). Transforming growth factor beta1 signaling via interaction with cell surface Hyal-2 and recruitment of WWOX/WOX1. J. Biol. Chem. 284, 16049-16059.
43. Hu, B. S., Tan, J. W., Zhu, G. H., Wang, D. F., Zhou, X., and Sun, Z. Q. (2012). WWOX induces apoptosis and inhibits proliferation of human hepatoma cell line SMMC-7721. World J. Gastroenterol. 18, 3020-3026.
44. Huang, H., Lin, H., Zhang, X., and Li, J. (2012). Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-kappaB-dependent pathway. Oncol. Rep. 27, 2050-2056.
45. Ishii, H., and Furukawa, Y. (2004). Alterations of common chromosome fragile sites in hematopoietic malignancies. Int. J. Hematol. 79, 238-242.
46. Janouskova, H., Maglott, A., Leger, D. Y., Bossert, C., Noulet, F., Guerin, E., et al. (2012). Integrin alpha5beta1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. Cancer Res. 72, 3463-3470.
47. Jin, C., Ge, L., Ding, X., Chen, Y., Zhu, H., Ward, T., et al. (2006). PKA-mediated protein phosphorylation regulates ezrin-WWOX interaction. Biochem. Biophys. Res. Commun. 341, 784-791.
48. Johannessen, T. C., and Bjerkvig, R. (2012). Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev. Anticancer Ther. 12, 635-642.
49. Junker, N., Latini, S., Petersen, L. N., and Kristjansen, P. E. (2003). Expression and regulation patterns of hyaluronidases in small cell lung cancer and glioma lines. Oncol. Rep. 10, 609-616.
50. Kanzawa, T., Bedwell, J., Kondo, Y., Kondo, S., and Germano, I. M. (2003). Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J. Neurosurg. 99, 1047-1052.
51. Kitange, G. J., Mladek, A. C., Carlson, B. L., Schroeder, M. A., Pokorny, J. L., Cen, L., et al. (2012). Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin. Cancer Res. 18, 4070-4079.
52. Knizhnik, A. V., Roos, W. P., Nikolova, T., Quiros, S., Tomaszowski, K. H., Christmann, M., et al. (2013). Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS ONE 8:e55665. doi:10.1371/journal.pone.0055665
53. Kohsaka, S., Wang, L., Yachi, K., Mahabir, R., Narita, T., Itoh, T., et al. (2012). STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol. Cancer Ther. 11, 1289-1299.
54. Kosla, K., Pluciennik, E., Kurzyk, A., Jesionek-Kupnicka, D., Kordek, R., Potemski, P., et al. (2011). Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme. J. Neurooncol. 101, 207-213.
55. Kuroki, T., Yendamuri, S., Trapasso, F., Matsuyama, A., Aqeilan, R. I., Alder, H., et al. (2004). The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin. Cancer Res. 10, 2459-2465.
56. Lai, F. J., Cheng, C. L., Chen, S. T., Wu, C. H., Hsu, L. J., Lee, J. Y., et al. (2005). WOX1 is essential for UVB irradiation-induced apoptosis and down-regulated via translational blockade in UVB-induced cutaneous squamous cell carcinoma in vivo. Clin. Cancer Res. 11, 5769-5777.
57. Lane, D., and Levine, A. (2010). p53 Research: the past thirty years and the next thirty years. Cold Spring Harb. Perspect. Biol. 2, a000893.
58. Lefranc, F., Brotchi, J., and Kiss, R. (2005). Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 23, 2411-2422.
59. Li, M. Y., Lai, F. J., Hsu, L. J., Lo, C. P., Cheng, C. L., Lin, S. R., et al. (2009). Dramatic co-activation of WWOX/WOX1 with CREB and NF-kappaB in delayed loss of small dorsal root ganglion neurons upon sciatic nerve transection in rats. PLoS ONE 4:e7820. doi:10.1371/journal.pone.0007820
60. Li, S., Liang, Z., Xu, L., and Zou, F. (2012). MicroRNA-21: a ubiquitously expressed pro-survival factor in cancer and other diseases. Mol. Cell. Biochem. 360, 147-158.
61. Lin, H. P., Chang, J. Y., Lin, S. R., Lee, M. H., Huang, S. S., Hsu, L. J., et al. (2011). Identification of an in vivo MEK/WOX1 complex as a master switch for apoptosis in T cell leukemia. Genes Cancer 2, 550-562.
62. Menendez, D., Inga, A., and Resnick, M. A. (2009). The expanding universe of p53 targets. Nat. Rev. Cancer 9, 724-737.
63. Moncada, S., Higgs, E. A., and Colombo, S. L. (2012). Fulfilling the metabolic requirements for cell proliferation. Biochem. J. 446, 1-7.
64. Murai, T., Miyazaki, Y., Nishinakamura, H., Sugahara, K. N., Miyauchi, T., Sako, Y., et al. (2004). Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. J. Biol. Chem. 279, 4541-4550.
65. Nakada, M., Furuta, T., Hayashi, Y., Minamoto, T., and Hamada, J. (2012). The strategy for enhancing temozolomide against malignant glioma. Front. Oncol. 2:98. doi:10.3389/fonc.2012.00098
66. Nakayama, S., Semba, S., Maeda, N., Aqeilan, R. I., Huebner, K., and Yokozaki, H. (2008). Role of the WWOX gene, encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells. Cancer Sci. 99, 1370-1376.
67. Nishikawa, R. (2010). Standard therapy for glioblastoma-a review of where we are. Neurol. Med. Chir. (Tokyo) 50, 713-719.
68. O'Keefe, L. V., Colella, A., Dayan, S., Chen, Q., Choo, A., Jacob, R., et al. (2011). Drosophila orthologue of WWOX, the chromosomal fragile site FRA16D tumour suppressor gene, functions in aerobic metabolism and regulates reactive oxygen species. Hum. Mol. Genet. 20, 497-509.
69. Oliva, C. R., Moellering, D. R., Gillespie, G. Y., and Griguer, C. E. (2011). Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS ONE 6:e24665. doi:10.1371/journal.pone.0024665
70. Pollack, I. F., Hamilton, R. L., Sobol, R. W., Burnham, J., Yates, A. J., Holmes, E. J., et al. (2006). O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J. Clin. Oncol. 24, 3431-3437.
71. Ray, P. S., Grover, R., and Das, S. (2006). Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep. 7, 404-410.
72. Roos, W. P., Batista, L. F., Naumann, S. C., Wick, W., Weller, M., Menck, C. F., et al. (2007). Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26, 186-197.
73. Salah, Z., Alian, A., and Aqeilan, R. I. (2012). WW domain-containing proteins: retrospectives and the future. Front. Biosci. 17, 331-348.
74. Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., Weller, M., et al. (2008). Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res. 14, 2900-2908.
75. Shi, L., Chen, J., Yang, J., Pan, T., Zhang, S., and Wang, Z. (2010). MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 1352, 255-264.
76. Silber, J. R., Bobola, M. S., Blank, A., and Chamberlain, M. C. (2012). O(6)-Methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim. Biophys. Acta 1826, 71-82.
77. Squatrito, M., Brennan, C. W., Helmy, K., Huse, J. T., Petrini, J. H., and Holland, E. C. (2010). Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 18, 619-629.
78. Stupp, R., Hegi, M. E., Mason, W. P., Van Den Bent, M. J., Taphoorn, M. J., Janzer, R. C., et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466.
79. Su, W. P., Chen, S. H., Chen, S. J., Chou, P. Y., Huang, C. C., and Chang, N. S. (2012). "WW Domain-containing oxidoreductase is a potential receptor for sex steroid hormones," in Sex Hormones, ed. R. K. Dubey (Rijeka: InTech), 333-351.
80. Sun, S., Lee, D., Lee, N. P., Pu, J. K., Wong, S. T., Lui, W. M., et al. (2012). Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. J. Neurooncol. 109, 467-475.
81. Sun, Y., Wenger, L., Rutter, J. L., Brinckerhoff, C. E., and Cheung, H. S. (1999). p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J. Biol. Chem. 274, 11535-11540.
82. Villalva, C., Cortes, U., Wager, M., Tourani, J. M., Rivet, P., Marquant, C., et al. (2012). O6-methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions. Int. J. Mol. Sci. 13, 6983-6994.
83. Voss, V., Senft, C., Lang, V., Ronellenfitsch, M. W., Steinbach, J. P., Seifert, V., et al. (2010). The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol. Cancer Res. 8, 1002-1016.
84. Wang, J. Y., and Edelmann, W. (2006). Mismatch repair proteins as sensors of alkylation DNA damage. Cancer Cell 9, 417-418.
85. Yoshida, T., Matsuda, Y., Naito, Z., and Ishiwata, T. (2012). CD44 in human glioma correlates with histopathological grade and cell migration. Pathol. Int. 62, 463-470.
86. Zhang, P., Jia, R., Ying, L., Liu, B., Qian, G., Fan, X., et al. (2012a). WWOX-mediated apoptosis in A549 cells mainly involves the mitochondrial pathway. Mol. Med. Report 6, 121-124.
87. Zhang, J., Stevens, M. F., and Bradshaw, T. D. (2012b). Temozolomide: mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 5, 102-114.